Chronic obstructive pulmonary disease (COPD), a major cause of death and disability, is attributed to an abnormal inflammatory response by the lungs to noxious substances, primarily from cigarette smoke. Although oxidative stress is regarded as central to the pathogenesis of COPD, very few studies have examined the effects of antioxidants in this condition. This was a randomized, double-blind, placebo-controlled study on the effects of melatonin in COPD. Thirty-six consecutive patients with clinically stable moderate to very severe COPD (30 men; mean±S.D.=66.6±7.8yr) were randomized to receive 3mg melatonin (N=18) or placebo for 3 months. Oxidative stress was evaluated by 8-isoprostane levels in exhaled breath condensate at baseline (T0) and after one (T1), two (T2), and three months (T3) of treatment. Additionally, exhaled breath condensate levels of IL-8, dyspnea severity (Medical Research Council scale), lung function (spirometry), and functional exercise capacity (six min walk test) were compared at baseline and after treatment. Patients receiving melatonin showed a decrease in 8-isoprostane (T0: mean±S.E.M.=20.41±2.92pg/mL; T1: 18.56±2.68pg/mL; T2: 12.68±2.04pg/mL; T3: 12.70±2.18pg/mL; P=0.04; repeated measures ANOVA) with significant differences from baseline after 2 (P=0.03) and 3months (P=0.01). Dyspnea was improved by melatonin (P=0.01), despite no significant changes in lung function or exercise capacity. Placebo-treated patients, but not those who were given melatonin, showed an increase in IL-8 (P=0.03). In summary, melatonin administration reduced oxidative stress and improved dyspnea in COPD. Further studies are necessary to determine the potential role for melatonin in the long-term management of these patients.

centers such as the city of São Paulo ranges from 6% to over 15%, depending on the diagnostic criteria adopted.(4) The fifth leading cause of death worldwide, COPD will have reached, according to recent estimates, the third position by 2030.(3) The increase in the mortality rate for COPD contrasts with the marked reduction in the mortality rate for diseases such as cancer, IntroductionWorldwide, COPD is a health problem with severe economic and social repercussions; at the personal level, COPD constitutes a major cause of patient disability and of low quality of life for patients and their caregivers.(1,2) According to the World Health Organization, 80 million people suffer from moderate or severe COPD. AbstractWorldwide, COPD is a major cause of morbidity and mortality. The clinical and functional manifestations of COPD result from lung injury occurring through various mechanisms, including oxidative stress, inflammation, protease-antiprotease imbalance and apoptosis. Oxidative stress is central to the pathogenesis of COPD, since it can directly damage lung structures and exacerbate the other mechanisms involved. The cellular and molecular events involved in such lung injury are believed to occur long before the clinical and functional expression of COPD. Although the use of bronchodilators is currently the principal treatment for COPD, bronchodilators have little or no effect on disease progression. A better understanding of the pathogenesis of COPD, together with renewed efforts in basic and clinical research, will allow the diagnosis of COPD at a pre-clinical stage and provide more appropriate monitoring of disease activity, as well as leading to the development of novel therapeutic agents that will effectively prevent the progression of the disease.Keywords: Pulmonary disease, chronic obstructive; Oxidative stress; Oxidants; Antioxidants; Inflammation. ResumoA DPOC é uma causa importante de morbidade e mortalidade em escala global. As manifestações clínicas e funcionais da DPOC resultam de danos pulmonares provocados por um conjunto de mecanismos, incluindo o estresse oxidativo, a inflamação, o desequilíbrio do sistema protease-antiprotease e a apoptose. O estresse oxidativo é central na gênese da DPOC, pois além de provocar dano direto às estruturas pulmonares, amplifica os demais mecanismos. Os eventos celulares e moleculares responsáveis pelo dano pulmonar antecedem em muito a expressão clínica e funcional da DPOC. Os broncodilatadores, principais drogas empregadas atualmente no tratamento da DPOC, não são eficazes em reduzir a progressão da doença. Avanços na compreensão da patogênese da DPOC aliados a esforços renovados na pesquisa básica e clínica deverão permitir sua detecção na fase pré-clínica e possibilitar um monitoramento mais adequado de sua atividade, além de permitir a introdução de novas modalidades de agentes terapêuticos capazes de impedir eficazmente sua progressão.

Objective: To evaluate the association between degree of asthma control and health-related quality of life in patients with moderate or severe asthma. Methods: This was a descriptive observational study involving 59 outpatients with moderate or severe asthma under treatment at the Asthma Outpatient Clinic of the Federal University of Ceará Walter Cantídio University Hospital, in the city of Fortaleza, Brazil. The patients were evaluated regarding sociodemographic and clinical characteristics, as well as spirometric parameters. The asthma control status was assessed using the asthma control test (ACT), and quality of life was assessed using the Saint George's Respiratory Questionnaire (SGRQ). Results: The mean age of the patients was 55.0 ± 12.4 years, and 76.3% were female. The ACT score showed statistically significant negative correlations with all SGRQ scores: total (r = −0.72); symptoms (r = −0.78); activity (r = −0.67); and impact (r = −0.68). Multiple regression analysis showed that the most robust predictive variables for SGRQ total score were ACT score (coefficient = −3.18; 95% CI: −4.14 to −2.23) and duration of disease (coefficient = −0.29; 95% CI: −0.54 to −0.03). The ACT score also explained the linear variation of the SGRQ domains: symptoms (coefficient = −3.41; 95% CI: −4.45 to −2.37); activity (coefficient = −3.07; 95% CI: −4.57 to −1.57); and impact (coefficient = −2.68; 95% CI: −3.71 to −1.65). Conclusions: The degree of asthma control appears to have a significant impact on health-related quality of life.Keywords: Asthma/prevention and control; Quality of life; Questionnaires. ResumoObjetivo: Avaliar a associação entre o estado de controle da asma e a qualidade de vida relacionada à saúde em pacientes com asma moderada ou grave. Métodos: Estudo descritivo observacional com 59 pacientes portadores de asma moderada ou grave, acompanhados no Ambulatório de Asma do Hospital Universitário Walter Cantídio da Universidade Federal do Ceará, em Fortaleza (CE). Os pacientes foram avaliados quanto a dados sociodemográficos, clínicos e espirométricos. O estado de controle da asma foi avaliado através do asthma control test (ACT) e a qualidade de vida através do Saint George's Respiratory Questionnaire (SGRQ). Resultados: A média de idade dos pacientes foi de 55,0 ± 12,4 anos, e 76,3% eram do sexo feminino. Foram observadas correlações negativas significantes entre os escores do ACT e todos os escores do SGRQ: total (r = −0,72); sintomas (r = −0,78); atividade (r = −0,67); e impactos (r = −0,68). A análise de regressão múltipla mostrou que o escore do SGRQ total teve como variáveis preditivas mais robustas o escore do ACT (coeficiente = −3,18; IC95%: −4,14 a −2,23) e tempo de doença (coeficiente = −0,29; IC95%: −0,54 a −0,03). O escore do ACT também explicou linearmente a variação do SGRQ em seus domínios: sintomas (coeficiente = −3,41 e IC95%: −4,45 a −2,37); atividade (coeficiente = −3,07 e IC95%: −4,57 a −1,57); e impactos (coeficiente = −2,68 e IC95%: −3,71 a −1,65). Conclusões: Na amostra estud...

No abstract